What's in the Neuromuscular Junction Literature?
Journal
Journal of clinical neuromuscular disease
ISSN: 1537-1611
Titre abrégé: J Clin Neuromuscul Dis
Pays: United States
ID NLM: 100887391
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
27
5
2020
Statut:
ppublish
Résumé
Four retrospective studies from the United States, Europe, and Asia address outcomes in juvenile myasthenia gravis. Common features include earlier onset with ocular myasthenia gravis (MG) and generally good outcomes overall. Patients who were seronegative, had equivocal acetylcholine receptor (AChR) antibodies, or had only clustered AChR antibodies had better outcomes. An article highlighting the utility of median nerve slow-repetitive stimulation is reviewed and another showing the high sensitivity of repetitive nerve stimulation in myasthenic crisis is covered. Two articles address the thymus and thymectomy in non-AChR antibody-positive autoimmune MG. Longer term data on eculizumab as well as studies of cyclophosphamide, rituximab, and tacrolimus are summarized. Other topics include the possible role of statins in MG and central nervous system autoimmune comorbidities.
Identifiants
pubmed: 32453095
doi: 10.1097/CND.0000000000000285
pii: 00131402-202006000-00002
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
195-204Références
Castro D, Derisavlfard S, Anderson M, et al. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscl Disord. 2013;14:95–102.
Phillips LH II. The epidemiology of myasthenia gravis. Ann NY Acad Sci. 2003;998:407–412.
McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34:171–183.
Xu L, Castro D, Reisch JS, et al. Response to treatment in pediatric ocular myasthenia gravis. Muscle Nerve. 2019;1–5.
Domiza V, Sithara R, Pinki M, et al. Predictive myasthenia gravis prognostic factors for drug free remission. Neuromuscul Disord. 2019. 10.1016/j.nmd.2019.11.008.
doi: 10.1016/j.nmd.2019.11.008
Chou C, Su I, Chou IJ, et al. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study. BMC Neurol. 2019;19:170–179.
Jastrzebska A, Jastrzebska M, Ryniewicz B, et al. Treatment outcome in juvenile onset myasthenia gravis. Muscle Nerve. 2019;59:549–554.
Lee TH, Li Y. Consideration of repetitive nerve stimulation of the median nerve in patients being evaluated for myasthenia gravis. Muscle Nerve. 2019;60:658–661.
Oh Aj, Jeong D, Lee I, et al. Repetitive nerve stimulation test in myasthenic crisis. Muscle Nerve. 2019;59:544–548.
Nicolau S, Kao JC, Liewluck T, et al. Trouble at the junction when myopathy and myasthenia overlap. Muscle Nerve. 2019;60:648–657.
Luo HY, Zhao L, Mao CY, et al. Novel compound heterozygous GFPT1 mutations in a family with limb girdle myasthenia with tubular aggregates. Neuromuscul Disord. 2019;29:549–553.
Gras-Champel V, Batteux B, Masmoudi K, et al. Statin-induced myasthenia: a disproportionality analysis of the WHOs Vigibase pharmacovigilance database. Muscle Nerve. 2019;60:382–386.
Song RH, Yao QM, Wang B, et al. Thyroid disorders in patients with myasthenia gravis: a systematic review and meta-analysis. Autoimmun Rev. 2019;10:102368.
Kimura K, Okada Y, Fujii C, et al. Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis. J Neurol. 2019;266:2743–2751.
Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. New Engl J Med. 2016;375:511–522.
Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody negative MG. Ann Neurol. 2005;57:444–448.
Clifford KM, Hobson-Webb LD, Benatar M, et al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle Nerve. 2019;59:404–410.
Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimun. 2014;54:139–145.
Koneczny I, Rennspiess D, Marcuse F, et al. Characterization of they thymus in Lrp4 myasthenia gravis: four cases. Autoimmun Rev. 2019;18:50–55.
Chang CC, Lin TM, Chang YS, et al. Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study. Rheumatology. 2019;58:135–143.
Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Lancet Neurol. 2017;16:976–986.
Muppidi S, Utsugisawa K, Benatar M, et al. Long term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14–24.
Edmundson CN, Guidon AC. Eculizumab: a complementary addition to existing long term therapies for myasthenia gravis. Muscle Nerve. 2019;60:7–9.
Andersen H, Mantegazza R, Wang JJ, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019;28:2247–2254.
Gomez-Figueroa E, Garcia-Trejo S, Bazan-Rodriguez L, et al. Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J Neurol. 2019. 10.1007/s00415-019-09622-4.
doi: 10.1007/s00415-019-09622-4
Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019;266:699–706.
Kim YH, Young Shin H, Kim SM, et al. Long term safety and efficacy of tacrolimus in myasthenia gravis. Yonsei Med J. 2019;60:633–639.
Wang L, Xi J, Zhang S, et al. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: a single arm meta-analysis. J Clin Neurosci. 2019;63:160–167.